New Two-Pronged cell therapy tested for aggressive blood cancer
NCT ID NCT07003568
Summary
This early-stage study is testing the safety of a new type of personalized cell therapy for patients with multiple myeloma that has returned or stopped responding to other treatments and has spread to other tissues. Doctors will collect and modify a patient's own immune cells to attack the cancer using two different targets. The main goal is to see how safe this treatment is and what side effects it causes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Liquan Hospital
RECRUITINGShanghai, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.